552 Views

Instructional Course

Instructional Course - Available with the Platinum and Silver packages or Individual Course Ticket

045IC - Contemporary Pharmacotherapy for Overactive Bladder 2022: Monotherapy and Combined Pharmacotherapy to Optimize Treatment

Saturday, May 14, 2022

10:00 AM – 12:00 PM

Location: Room 204

Instructional Course Director(s)

Eric Scott Rovner, MD

MD
Medical University of South Carolina

Instructional Course Faculty(s)

Alan J. Wein, MD, PhD(hon) (he/him/his)

Professor with Tenure and Emeritus Chief of Urology and Associate Director, Resi
University of Pennsylvania
Christopher R. Chapple, MD,FEBU,FRCS,MBBS,BS (he/him/his)

Consultant Urological Surgeon
Sheffield Teaching Hospitals NHS Foundation Trust, University of Sheffield, Sheffield Hallam University

Learning Objectives:

Define the similarities and differences between the various oral pharmacotherapies for OAB.
Review the principles of physiology and pharmacotherapy for currently available agents, including the antimuscarinics and beta-3 agonists and combination therapy.
Explain the importance of setting proper patient expectations regarding treatment of OAB and the potential need for sequential and even additive therapies.
Analyze the clinical (and theoretical) advantages and limitations of currently available agents.
Discuss potential future pharmacological pathways and therapies for OAB.

Much has been written and debated about drug treatment of overactive bladder (OAB) over the past 2 decades. Nevertheless, the field continues to evolve. OAB pharmacotherapy remains an area of active investigation, and innovation. The publication of the recently updated AUA/Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) Guideline entitled, “Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults,” and the proceedings of the 7th International Consultation on Incontinence, as well as European Association of Urology (EAU) Guidelines have maintained considerable interest in this area amongst researchers and practitioners. This course will describe the physiological and pharmacological underpinnings of modern drug treatment of overactive bladder, review currently available agents and discuss agents in development.